Stockscreener 앱 받기
1.73
0.58%
0.01
시간 외 거래:
1.70
-0.03
-1.73%
전일 마감가:
$1.72
열려 있는:
$1.78
하루 거래량:
680.45K
Relative Volume:
0.70
시가총액:
$244.14M
수익:
$15.53M
순이익/손실:
$-52.71M
주가수익비율:
-3.4428
EPS:
-0.5025
순현금흐름:
$-59.00M
1주 성능:
-1.70%
1개월 성능:
+13.07%
6개월 성능:
+2.98%
1년 성능:
-22.42%
1일 변동 폭
$1.71
$1.78
1주일 범위
$1.70
$1.995
52주 변동 폭
$1.33
$3.10
Proqr Therapeutics N V Stock (PRQR) Company Profile
Compare PRQR vs VRTX, REGN, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PRQR
Proqr Therapeutics N V
|
1.73 | 242.73M | 15.53M | -52.71M | -59.00M | -0.5025 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-12 | 재개 | Oppenheimer | Outperform |
| 2025-04-29 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-04-29 | 개시 | Evercore ISI | Outperform |
| 2025-03-10 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-01-10 | 개시 | Oppenheimer | Outperform |
| 2024-10-29 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2023-11-08 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2023-03-30 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2022-12-22 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2022-02-14 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-02-11 | 다운그레이드 | Raymond James | Strong Buy → Mkt Perform |
| 2022-02-11 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-02-01 | 개시 | Raymond James | Strong Buy |
| 2021-05-03 | 개시 | Stifel | Buy |
| 2021-03-25 | 재확인 | Citigroup | Buy |
| 2020-11-03 | 재개 | Cantor Fitzgerald | Overweight |
| 2019-03-12 | 재확인 | Chardan Capital Markets | Buy |
| 2018-12-19 | 개시 | RBC Capital Mkts | Outperform |
| 2018-11-15 | 개시 | Citigroup | Buy |
| 2018-09-19 | 개시 | Evercore ISI | Outperform |
| 2017-09-26 | 재확인 | JMP Securities | Mkt Outperform |
| 2016-06-20 | 개시 | Chardan Capital Markets | Neutral |
| 2014-10-15 | 개시 | Deutsche Bank | Buy |
| 2014-10-13 | 개시 | H.C. Wainwright | Buy |
모두보기
Proqr Therapeutics N V 주식(PRQR)의 최신 뉴스
PRQR|ProQR Therapeutics NV|Price:1.720|Chg%:-0.070 - TradingKey
ProQR Therapeutics NV (PRQR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ProQR Therapeutics NV (PRQR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ProQR Therapeutics N.V. Revenue Breakdown – BMV:PRQR/N - TradingView
TradingKey - TradingKey
ProQR Therapeutics NV (PRQR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ProQR Therapeutics NV (PRQR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Privium Fund Management B.V. Increases Stake in ProQR Therapeuti - GuruFocus
Bart Filius Acquires Additional Shares in ProQR Therapeutics NV - GuruFocus
Form 4 ProQR Therapeutics N.V. For: 21 July By Investing.com - Investing.com South Africa
Proqr Therapeutics N.v. Insider Bought Shares Worth $257,925, According to a Recent SEC Filing - marketscreener.com
ProQR Therapeutics (PRQR) director purchases 150,000 Ordinary Shares - Stock Titan
ProQR Therapeutics (NASDAQ:PRQR) Stock Passes Above 50-Day Moving AverageHere's Why - MarketBeat
ProQR Therapeutics Virtual Investor Event Transcript - GuruFocus
ProQR Therapeutics (PRQR) Gains 1.8% as Shares Test Key Resistance Near $1.78Entry Point Alerts - dars.gov.et
ProQR Therapeutics N.V. SEC Filing (Jul 16, 2026) - Stock Titan
ProQR Therapeutics (NASDAQ: PRQR) details 3.0M-share resale and balance sheet - Stock Titan
Aescap group and Patrick Krol report ProQR (PRQR) shareholdings - Stock Titan
Insider Buying: CEO de Boer Daniel Anton Acquires 150,000 Shares of ProQR Therapeutics NV - GuruFocus
ProQR Therapeutics (NASDAQ:PRQR) CEO Boer Daniel Anton De Buys 150,000 Shares - MarketBeat
ProQR (PRQR) CEO lifts stake to 300,000 shares - Stock Titan
ProQR Therapeutics (PRQR) Faces Pressure at $1.73 After 1.7% DeclineSocial Sentiment - dars.gov.et
ProQR Therapeutics N.V. (NASDAQ:PRQR) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
ProQR (PRQR) CEO Daniel de Boer purchases 150,000 Ordinary Shares at $1.59 - Stock Titan
ProQR Therapeutics files prospectus for 3.03M share offering - scanx.trade
ProQR Therapeutics (PRQR) registers 3.03M shares for resale on Nasdaq - Stock Titan
ProQR prices $50M stock offering; secures $9.2M investment from Eli Lilly - MSN
ProQR Therapeutics: Human NTCP Data Strengthens The Axiomer Thesis (NASDAQ:PRQR) - Seeking Alpha
ProQR posts early-stage trial data for liver disease candidate - MSN
Insider Buying: ProQR Therapeutics Independent Non-Executive Director Bought €231k Of Shares - simplywall.st
PRQRProQR Therapeutics N.V Options - Finviz
PRQR Q1 2026 Earnings: EPS Misses Estimates as Clinical-Stage Biotech Advances PipelineEarnings Preview - dars.gov.et
Bart Filius Acquires 150,000 Shares of ProQR Therapeutics NV - GuruFocus
Form 13D/A ProQR Therapeutics N.V. For: 30 June By Investing.com - Investing.com South Africa
Van Herk group reports 10.9% ProQR (PRQR) ownership after share issuances - Stock Titan
ProQR (PRQR) director receives 14,595-share option grant at $1.42 strike - Stock Titan
Director Bart Filius buys 150,000 ProQR (PRQR) Ordinary Shares in open market - Stock Titan
ProQR Therapeutics N.V. Actuals & Estimates (TRADEGATE:0PQ) - TradingView
0PQ Forecast — Price Target — Prediction for 2027 - TradingView
PRQR Maintained by Evercore ISI Group -- Price Target Raised to $6.00 - GuruFocus
Small-cap ProQR Therapeutics secures funding from Eli Lilly on early trial success - MSN
ProQR Raises $59 Million in Equity Offering and Eli Lilly Private Placement - The Globe and Mail
ProQR Therapeutics (NASDAQ: PRQR) raises capital; Lilly to purchase 5.1M shares - Stock Titan
PRQR Maintains Buy Rating by Jones Trading -- Price Target Lowered to $10.00 - GuruFocus
PRQR Maintained by Chardan Capital -- Price Target Lowered to $3 - GuruFocus
ProQR Therapeutics N.V. Actuals & Estimates (DUS:0PQ) - TradingView
ProQR Therapeutics N.V. Actuals & Estimates (NASDAQ:PRQR) - TradingView
Chardan Research Adjusts ProQR Therapeutics Price Target to $3 From $4, Maintains Buy Rating - marketscreener.com
Small-Cap ProQR Therapeutics Secures Funding From Eli Lilly On Early Trial Success - Sahm
ProQR (PRQR) prices share offering and Eli Lilly private placement - Stock Titan
Price to book forward of ProQR Therapeutics N.V. – NASDAQ:PRQR - TradingView
Proqr Therapeutics N V (PRQR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.97%
0.83%
자본화:
|
볼륨(24시간):